Anteris Technologies Global Corp. (ASX:AVR) has filed its Form 10-Q Quarterly Report for the quarter ended September 30, 2026 with the U.S. Securities and Exchange Commission, disclosing aggregate payments to related parties and their associates of US$576 thousand during the third quarter of 2026.

Key Points

  • Form 10-Q Quarterly Report for the quarter ended September 30, 2026 filed with the SEC
  • Aggregate payments to related parties and their associates totalled US$576 thousand in Q3 2026
  • Related party payments included fees to non-executive directors and salary payments to the CEO, President and CFO
  • All related party payments were included in cash flows from operating activities; no such payments were included in cash flows from investing activities
  • As of November 9, 2026, the number of shares outstanding was 97,493,429

Form 10-Q Filing for Quarter Ended September 30, 2026

Anteris Technologies Global Corp. lodged its Form 10-Q with the SEC for the quarterly period ended September 30, 2026. The report includes condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP), denominated in U.S. dollars. Supplementary information has been provided in connection with the Form 10-Q to satisfy the company's ongoing disclosure obligations under the ASX Listing Rules, prepared in accordance with waiver conditions granted by the ASX in relation to 4.7C for quarterly activity reports.

Related Party Payments in Q3 2026

During the third quarter of 2026, the aggregate amount of payments to related parties and their associates was US$576 thousand. According to the filing, the quarterly amount includes fees paid to non-executive directors, as well as salary payments to the CEO, President and CFO. These payments were included in cash flows from operating activities. The filing states there were no payments to related parties or their associates included in cash flows from investing activities during the quarter.

Company Description and Share Count

Anteris Technologies Global Corp. is listed on both the Nasdaq Global Market and ASX under the ticker AVR. The company is described in the filing as a global healthcare company focused on designing, developing and commercialising medical devices to restore healthy heart function, with its lead product being the DurAVR® THV, a balloon-expandable transcatheter heart valve made using a single piece of moulded ADAPT® tissue. As of November 9, 2026, the number of shares of common stock outstanding was 97,493,429. The filing was authorised for release by the Board of Directors.